Literature DB >> 15715976

The evolutionary history of the CCR5-Delta32 HIV-resistance mutation.

Alison P Galvani1, John Novembre.   

Abstract

The CCR5 chemokine receptor is exploited by HIV-1 to gain entry into CD4+ T cells. A deletion mutation (Delta32) confers resistance against HIV by obliterating the expression of the receptor on the cell surface. Intriguingly, this allele is young in evolutionary time, yet it has reached relatively high frequencies in Europe. These properties indicate that the mutation has been under intense positive selection. HIV-1 has not exerted selection for long enough on the human population to drive the CCR5-Delta32 allele to current frequencies, fueling debate regarding the selective pressure responsible for rise of the allele. The allele exists at appreciable frequencies only in Europe, and within Europe, the frequency is higher in the north. Here we review the population genetics of the CCR5 locus, the debate over the historical selective pressure acting on CCR5-Delta32, the inferences that can potentially be drawn from the geographic distribution of CCR5-Delta32 and the role that other genetic polymorphisms play in conferring resistance against HIV. We also discuss parallel evolution that has occurred at the CCR5 locus of other primate species. Finally, we highlight the promise that therapies based on interfering with the CCR5 receptor could have in the treatment of HIV.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15715976     DOI: 10.1016/j.micinf.2004.12.006

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  42 in total

1.  Distribution of CCR-5Δ32, CCR2-64I, and SDF-1-3'A alleles among Jordanians.

Authors:  Omar F Khabour; Laila J Abu-Haweleh; Karem H Alzoubi
Journal:  AIDS Res Hum Retroviruses       Date:  2012-07-31       Impact factor: 2.205

2.  Polymorphisms in chemokine receptor genes and susceptibility to Kawasaki disease.

Authors:  W B Breunis; M H Biezeveld; J Geissler; I M Kuipers; J Lam; J Ottenkamp; A Hutchinson; R Welch; S J Chanock; T W Kuijpers
Journal:  Clin Exp Immunol       Date:  2007-08-02       Impact factor: 4.330

3.  Estimation of 2Nes from temporal allele frequency data.

Authors:  Jonathan P Bollback; Thomas L York; Rasmus Nielsen
Journal:  Genetics       Date:  2008-05       Impact factor: 4.562

4.  Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras.

Authors:  Lee Adam Wheeler; Radiana Trifonova; Vladimir Vrbanac; Emre Basar; Shannon McKernan; Zhan Xu; Edward Seung; Maud Deruaz; Tim Dudek; Jon Ivar Einarsson; Linda Yang; Todd M Allen; Andrew D Luster; Andrew M Tager; Derek M Dykxhoorn; Judy Lieberman
Journal:  J Clin Invest       Date:  2011-05-16       Impact factor: 14.808

5.  The physician-scientist, the state, and the oath: thoughts for our times.

Authors:  Barry S Coller
Journal:  J Clin Invest       Date:  2006-10       Impact factor: 14.808

Review 6.  Evolution by gene loss.

Authors:  Ricard Albalat; Cristian Cañestro
Journal:  Nat Rev Genet       Date:  2016-04-18       Impact factor: 53.242

7.  Association of two functional polymorphisms in the CCR5 gene with juvenile rheumatoid arthritis.

Authors:  S Prahalad; J F Bohnsack; L B Jorde; A Whiting; B Clifford; D Dunn; R Weiss; M Moroldo; S D Thompson; D N Glass; M J Bamshad
Journal:  Genes Immun       Date:  2006-06-15       Impact factor: 2.676

8.  Communication of pharmacogenetic research results to HIV-infected treated patients: standpoints of professionals and patients.

Authors:  Grégoire Moutel; Nathalie Duchange; François Raffi; Lama I Sharara; Ioannis Théodorou; Violaine Noël; Sandrine de Montgolfier; Ingrid Callies; François Bricaire; Christian Hervé; Catherine Leport
Journal:  Eur J Hum Genet       Date:  2005-09       Impact factor: 4.246

9.  Genetic variation within the gene encoding the HIV-1 CCR5 coreceptor in two South African populations.

Authors:  Anabela C P Picton; Maria Paximadis; Caroline T Tiemessen
Journal:  Infect Genet Evol       Date:  2010-03-04       Impact factor: 3.342

10.  Human genomics and preparedness for infectious threats.

Authors:  Nicole F Dowling; Marta Gwinn; Alison Mawle
Journal:  Genome Med       Date:  2009-12-29       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.